Sharewise Webinar With CEO Dr Daniel Tillett
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Race Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability...
Demystifying Clinical Trials & Approval Processes
Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Race Oncology’s journey through the drug development process. Dr Tillett...
WTF With Race Oncology: Changing The Chemo Game – Stockhead
WTF With Race Oncology: Changing The Chemo Game – Stockhead
Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through...
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Looks To Accelerate Clinical Development Of Bisantrene
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax...
